FDA Inspection 1028333 — Resilience US, Inc.
The FDA completed an inspection of Resilience US, Inc. on September 14, 2017 in Allston, MA. The inspection was classified NAI (No Action Indicated — no objectionable conditions were found). Product area: Drugs.
Inspection Details
- Classification
- No Action Indicated (NAI) (NAI)
- End Date
- September 14, 2017
- Fiscal Year
- 2017
- Product Type
- Drugs
- Project Area
- Bioresearch Monitoring
- Location
- Allston, MA (United States)
Additional Details
Risk Evaluation and Mitigation Strategies (REMS)